Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4816)
All Articles published online
|
Publishing Process of This Article
|
Aug 15, 2024 (publication date) through May 10, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Buddhavarapu V, Dhillon G, Grewal H, Sharma P, Kashyap R, Surani S. Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review. World J Diabetes 2024; 15(8): 1793-1801 [PMID: 39192866 DOI: 10.4239/wjd.v15.i8.1793] |
|
|
|
| All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. | |
| For: | Buddhavarapu V, Dhillon G, Grewal H, Sharma P, Kashyap R, Surani S. Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review. World J Diabetes 2024; 15(8): 1793-1801 [PMID: 39192866 DOI: 10.4239/wjd.v15.i8.1793] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v15/i8/1793.htm |
| Number | Citing Articles |
| 1 |
Maria Aurora Roma Wilson, Paolo Pozzilli. What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?. Journal of Diabetes and its Complications 2025; 39(10): 109132 doi: 10.1016/j.jdiacomp.2025.109132
|
| 2 |
Maria Aurora Roma-Wilson, Paolo Pozzilli. Corrigendum to ‘What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?’ [JDC, Vol. 39, Issue 10, October 2025, 109132]. Journal of Diabetes and its Complications 2026; 40(3): 109230 doi: 10.1016/j.jdiacomp.2025.109230
|
| 3 |
Ana M. Wägner, Marta Hernández García. Estado de la prevención de la diabetes mellitus tipo 1: promesas y realidades. Endocrinología, Diabetes y Nutrición 2025; 72(1): 1 doi: 10.1016/j.endinu.2024.10.002
|
| 4 |
Doaa Zaitoon, Hussein Zaitoon. Teplizumab for stage 2 type 1 diabetes: a new era in pediatric diabetes prevention. European Journal of Pediatrics 2025; 184(11) doi: 10.1007/s00431-025-06520-y
|
| 5 |
Ana M. Wägner, Marta Hernández García. Status of type 1 diabetes mellitus prevention: promises and realities. Endocrinología, Diabetes y Nutrición (English ed.) 2025; 72(1): 1 doi: 10.1016/j.endien.2024.12.004
|
| 6 |
Changjiang Wang, Yingshi Wang, Wenwen Zheng, Junli Wu, Yufen Shen, Jianjun Ji, Pengfei Du. Assessment of Adverse Events of Teplizumab: A Real-world Pharmacovigilance Study Based on the FDA Adverse Event Reporting System. Clinical Therapeutics 2025; 47(12): 1143 doi: 10.1016/j.clinthera.2025.09.009
|
| 7 |
Anette-Gabriele Ziegler, Eda Cengiz, Thomas W H Kay. The future of type 1 diabetes therapy. The Lancet 2025; 406(10511): 1520 doi: 10.1016/S0140-6736(25)01438-2
|
| 8 |
Sahana Mahesh, Matthew Anson, Rayaz A. Malik, Daniel J. Cuthbertson, Uazman Alam. Real‐world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement. Diabetes, Obesity and Metabolism 2026; 28(3): 2425 doi: 10.1111/dom.70354
|
| 9 |
Ha Rim Yang, Ji Woong Kim, Hye Lim Choi, Hyunbo Shim, Sukmook Lee. Development of a novel CD3ε-specific human antibody for selective modulation of T cell activation. International Journal of Biological Macromolecules 2025; 320: 145859 doi: 10.1016/j.ijbiomac.2025.145859
|